After a magnesium-ibogaine treatment, Special Operations veterans with traumatic brain injury showed improvements in daily functioning and in PTSD, depression, and anxiety.
A 2024 study gave a magnesium-ibogaine treatment to Special Operations veterans living with traumatic brain injury and its mental-health after-effects.
Thirty male Special Operations veterans living with the after-effects of traumatic brain injury — including PTSD, depression, and anxiety — received a single ibogaine treatment paired with magnesium (to reduce ibogaine's known heart risks), alongside other supportive therapies. Right after treatment and a month later, their day-to-day functioning had improved, and a month out their PTSD, depression, and anxiety symptoms had all dropped, with no serious adverse events. But this was an observational study with no comparison group, and the ibogaine was given together with other therapies, so the authors themselves call for controlled trials to confirm whether the treatment is what caused the change.
This prospective observational study (n=30) delivered the Magnesium-Ibogaine (MISTIC) protocol — ibogaine with magnesium coadministration to mitigate cardiac risk — to male Special Operations Forces veterans with predominantly mild TBI, together with complementary treatment modalities. Functioning (WHODAS) improved immediately (d=0.74) and at one month (d=2.20). At one month, PTSD (CAPS-5, d=2.54), depression (MADRS, d=2.80), and anxiety (HAM-A, d=2.13) were all significantly improved, with no unexpected or serious adverse events.
The effect sizes are very large, but the design is observational and single-arm: no control group, no blinding, no randomization, so improvement cannot be separated from placebo response, expectancy, regression to the mean, or the complementary therapies given alongside ibogaine. The sample is small (n=30) and self-selected. Ibogaine carries a real risk of fatal cardiac arrhythmia; magnesium was used to mitigate it and no serious adverse events occurred here, but safety is not established at scale. The authors explicitly frame this as initial open-label evidence requiring controlled trials.
Ibogaine's evidence base in veterans is early and largely observational. A separate open-label program combining ibogaine with 5-MeO-DMT in Special Operations veterans reported large improvements in PTSD, depression, and anxiety sustained to six months (Davis et al., 2023). No randomized controlled trial of ibogaine for TBI or PTSD in veterans has yet been published; the trial's registration (NCT04313712) reflects the authors' stated need for controlled confirmation.
Read the full paper →